We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoassay Screens Risky Malaria Blood Donations

By LabMedica International staff writers
Posted on 22 Aug 2013
An enzyme-linked immunosorbent assay (ELISA) has been used to screen blood donations in an area highly endemic for malaria. More...


The main causative agent of malaria, Plasmodium falciparum, poses a threat on critical transfusions for road accident victims, pregnancy-related hemorrhages and child anemia enhancing the risk of transfusion-transmitted malaria (TTM).

Scientists at the University of Strasbourg (Alsace, France) collected blood in ethylenediaminetetraacetic acid (EDTA) tubes from 2,515 voluntary blood donors in Benin, over a period of 10 months, from May 2009 and March 2010. Microscopic examination was used to count parasites and parasite density (PD) was expressed as the number of parasites per µL of blood.


The plasmodium lactate dehydrogenase (pLDH) antigen detection was performed by a sandwich ELISA notably an ELISA-malaria antigen test (apDianv; Turnhout, Belgium) that detects pLDH via immunocapture. The apDia Antigen ELISA is an in vitro diagnostic immunoassay (IVD) for the qualitative determination of Plasmodium spp. Antibody screening was performed using a homemade ELISA-antibody test.


Among the 2,025 males and 488 females screened, the rate of asymptomatic Plasmodium carriage was 295/2,515 (11.7%). Males had a higher infection rate of 12.4% than did females at 8.8%. Parasite density was very low with between seven and100 parasites per µL of blood reported in 80% of donors with parasitaemia. Three malaria species were diagnosed: P. falciparum in 280/295 patients (95.0%), Plasmodium malariae in 14/295 (5.0%), and Plasmodium ovale in 1/295 (0.34%). The use of a highly sensitive assay enabled pan Plasmodium pLDH detection in 966/2,515 (38.4%) and malaria antibody prevalence was found in 1,859/2,515 (73.9%).


The authors concluded that detection of the pLDH antigen seems to be an adequate screening tool in endemic areas, for this antigen indicates parasite presence. Routine screening of all donated blood would prevent infected blood donations and reduce P. falciparum transmission in critical patients, such as children and pregnant women. This tool would also decrease medical prophylaxis in donation recipients and contribute to lower Plasmodium resistance. One drawback was that if the donors had taken self-treatment measures prior to blood donation, malaria infection was masked and pLDH detection failed. The study was published on August 8, 2013, in the Malaria Journal.

Related Links:
University of Strasbourg
apDia


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.